Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Orchestra Biomed Holdings Inc

OBIO ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Advanced Medical Equipment & Technology ·

USA Micro Cap Analyst: BUY

Last Close

$4.41

▼ -0.90%

Market Cap $265.06M · Vol 45.80K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$265.06M

Micro Cap

Div Yield

N/A

EPS Growth

-45.40%

YoY

RSI (14)

75.21

Momentum

Beta

0.51

vs Market

52W High

$5.40

18.33% below

52W Low

$2.20

100.45% above

Volume

45.80K

Avg 73.01K

P/B

4.42

Price-to-book

ROE

-121.81%

Return on equity

Free Float

67.09%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Orchestra Biomed Holdings Inc (OBIO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OBIO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.01%

+19.51%

+7.30%

+15.14%

YTD

+6.27%

+65.79%

-21.81%

-55.41%

Financials & Valuation

TTM · Annual

Total Revenue	$33.48M
Net Income	$-52,701,000.00
Revenue Growth (YoY)	-89.47%
Gross Margin	99.43%
Operating Margin	-154.73%
Net Profit Margin	-157.40%
ROE	-121.81%
ROA · ROIC	-55.18% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5.92
P/B	4.42
P/FCF	N/A
EPS Growth	-45.40%
Outstanding Shares	60.11M

Technical Indicators

50-Day SMA	$4.02
200-Day SMA	$4.18
RSI (14)	75.21
Beta	0.51
52-Week High	$5.40
52-Week Low	$2.20

Volume Today	45.80K
Avg Daily Volume (30D)	73.01K
Relative Volume	0.63x
Volatility (10D)	36.02
Volatility (30D)	36.69
Free Float	67.09%

Analyst Consensus

BUY

Current Price $4.41

Mean Target $12.33

52W Low$2.20 52W High$5.40

Current

Target

$2.20 $5.40

Current Analyst target

+179.67% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00W5FR3L1

ISINUS68572M1062

CountryUnited States of America

Sub-IndustryAdvanced Medical Equipment & Technology (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

TMO Thermo Fisher Scientific Inc -1.28% DHR Danaher Corp -0.71% ISRG Intuitive Surgical Inc -1.68% BSX Boston Scientific Corp +0.27% EW Edwards Lifesciences Corp -1.04%

Company Profile

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.